ATE213948T1 - Reovirus zur behandlung von neoplasmen - Google Patents

Reovirus zur behandlung von neoplasmen

Info

Publication number
ATE213948T1
ATE213948T1 AT98940002T AT98940002T ATE213948T1 AT E213948 T1 ATE213948 T1 AT E213948T1 AT 98940002 T AT98940002 T AT 98940002T AT 98940002 T AT98940002 T AT 98940002T AT E213948 T1 ATE213948 T1 AT E213948T1
Authority
AT
Austria
Prior art keywords
reovirus
neoplasms
treatment
neoplasm
pkr
Prior art date
Application number
AT98940002T
Other languages
English (en)
Inventor
Patrick W K Lee
James Strong
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ATE213948T1 publication Critical patent/ATE213948T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98940002T 1997-08-13 1998-08-12 Reovirus zur behandlung von neoplasmen ATE213948T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/911,383 US6110461A (en) 1997-08-13 1997-08-13 Reovirus for the treatment of neoplasia
PCT/CA1998/000774 WO1999008692A1 (en) 1997-08-13 1998-08-12 Reovirus for the treatment of neoplasia

Publications (1)

Publication Number Publication Date
ATE213948T1 true ATE213948T1 (de) 2002-03-15

Family

ID=25430159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98940002T ATE213948T1 (de) 1997-08-13 1998-08-12 Reovirus zur behandlung von neoplasmen

Country Status (14)

Country Link
US (9) US6110461A (de)
EP (3) EP1003534B1 (de)
JP (1) JP4291884B2 (de)
AT (1) ATE213948T1 (de)
AU (1) AU731810B2 (de)
CA (1) CA2283280C (de)
DE (2) DE1003534T1 (de)
DK (1) DK1003534T3 (de)
ES (1) ES2157870T3 (de)
GR (1) GR20010300030T1 (de)
IL (1) IL131598A (de)
NZ (1) NZ337493A (de)
PT (1) PT1003534E (de)
WO (1) WO1999008692A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
MXPA01010393A (es) * 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
EP1955703A1 (de) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viren für die Behandlung von zellulären, proliferativen Erkrankungen
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020156039A1 (en) * 2000-07-07 2002-10-24 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20020147996A1 (en) * 2000-07-07 2002-10-10 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
CA2428206C (en) * 2000-11-09 2005-09-27 Oncolytics Biotech Inc. Methods for the treatment of cellular proliferative disorders
JP2004513184A (ja) * 2000-11-20 2004-04-30 オンコリティクス　バイオテック，　インコーポレイティッド 固形腫瘍塊への最適なウイルス送達法
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
AU2002220416A1 (en) * 2000-12-01 2002-06-11 University Of Ottawa Oncolytic virus
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
EP1370643A1 (de) 2001-03-16 2003-12-17 Oncolytics Biotech, Inc. Methode zur extraktion von virus aus einer zellkultur
US7223388B2 (en) * 2001-08-03 2007-05-29 Board Of Regents, The Univeristy Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) * 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US7319001B2 (en) 2002-03-09 2008-01-15 Neurogenex Co., Ltd. High throughput system for producing recombinant viruses using site-specific recombination
DK1501921T4 (da) 2002-04-30 2012-10-08 Oncolytics Biotech Inc Forbedrede virusrensningsmetoder
ES2239928T3 (es) * 2002-05-09 2009-02-16 Oncolytics Biotech Inc. Metodo para reducir el dolor utilizando virus oncoliticos.
EP1944035A1 (de) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Verfahren zur Schmerzlinderung durch onkolytische Viren
AU2003238008A1 (en) * 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20060241178A1 (en) * 2002-12-30 2006-10-26 Immuneguard Llc Compositions and methods for treating lung cancer
EP1606411B1 (de) 2003-03-27 2008-12-10 Ottawa Health Research Institute Mutante vesicular stomatitis viren und deren verwendungen
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
MXPA06003318A (es) * 2003-09-26 2006-06-08 Novartis Ag Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad.
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1917351A4 (de) * 2005-08-01 2009-12-16 Univ Technologies Int Abgeschwächtes reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
AU2007215328A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
CA2678721C (en) 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
WO2009143611A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
KR101911964B1 (ko) 2010-09-02 2018-10-25 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 수포성 구내염 바이러스
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
WO2014204275A1 (ko) * 2013-06-21 2014-12-24 한국생명공학연구원 리오바이러스를 유효성분으로 함유하는 혈관신생 억제용 조성물
ES2796950T3 (es) 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
CN115867299A (zh) * 2020-05-20 2023-03-28 百洛克株式会社 用于预防或治疗癌症的药物组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
PT70556A (en) * 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) * 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
CA2045129A1 (en) * 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
AU5275290A (en) * 1989-04-11 1990-11-05 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
EP0931830B1 (de) * 1993-02-16 2001-03-07 Onyx Pharmaceuticals, Inc. Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
US5525342A (en) * 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
AU4352997A (en) 1996-08-30 1998-03-19 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
JP2001519175A (ja) 1997-10-09 2001-10-23 プロ − バイラス，インコーポレイテッド ウイルスを用いた新生物の処置
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
CA2428206C (en) * 2000-11-09 2005-09-27 Oncolytics Biotech Inc. Methods for the treatment of cellular proliferative disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
ES2386779T3 (es) * 2002-05-10 2012-08-30 Oncolytics Biotech Inc. Sensibilización de células neoplásicas frente a la terapia de radiación con virus oncolíticos
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
ZA200800246B (en) * 2005-08-31 2009-08-26 Oncolytics Biotech Inc Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
CA2678721C (en) * 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences

Also Published As

Publication number Publication date
EP1433483A1 (de) 2004-06-30
HK1028340A1 (en) 2001-02-16
CA2283280C (en) 2005-10-18
NZ337493A (en) 2000-12-22
US20050123513A1 (en) 2005-06-09
DE69804106D1 (de) 2002-04-11
US20040265271A1 (en) 2004-12-30
AU731810B2 (en) 2001-04-05
GR20010300030T1 (en) 2001-08-31
EP1003534B1 (de) 2002-03-06
IL131598A0 (en) 2001-01-28
US20020187125A1 (en) 2002-12-12
ES2157870T1 (es) 2001-09-01
DE1003534T1 (de) 2001-08-23
US20090098089A1 (en) 2009-04-16
IL131598A (en) 2005-03-20
US20090110665A1 (en) 2009-04-30
WO1999008692A1 (en) 1999-02-25
US6576234B2 (en) 2003-06-10
US6344195B1 (en) 2002-02-05
DE69804106T2 (de) 2002-08-14
AU8847198A (en) 1999-03-08
JP4291884B2 (ja) 2009-07-08
US6110461A (en) 2000-08-29
EP1003534A1 (de) 2000-05-31
DK1003534T3 (da) 2002-05-21
AU731810C (en) 1999-03-08
CA2283280A1 (en) 1999-02-25
US7476382B2 (en) 2009-01-13
ES2157870T3 (es) 2002-10-16
US7300650B2 (en) 2007-11-27
US6261555B1 (en) 2001-07-17
PT1003534E (pt) 2002-08-30
EP1213023A1 (de) 2002-06-12
US20010048920A1 (en) 2001-12-06
JP2002511886A (ja) 2002-04-16

Similar Documents

Publication Publication Date Title
ATE213948T1 (de) Reovirus zur behandlung von neoplasmen
EP0651633A4 (de) Phosphopeptide zur behandlung von zahnstein.
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE69008010D1 (de) Sauerstoffdelignifizierung und enzymatische Behandlung.
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
ATE400283T1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
DK221690A (da) Anvendelse af dimethylpolysiloxaner til behandling af sygdomme i det gastrointestinale omraade
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
ATE81455T1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
ES507444A0 (es) Procedimiento para inactivar virus de la fiebre aftosa.
NO970185L (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee